DadFinStart your free weekMyriad Genetics, Inc. (MYGN) stock score
$4.31 ▲ +2.62% today
Myriad Genetics, Inc. (MYGN) is a Diagnostics & Research company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 38.9 out of 100 on the Dad Score, a weak reading that places the business ahead of 39% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #542 of 974. Its strongest axis is price action; its weakest are valuation and quality.
Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →
The eight axes
Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.
Key numbers
What subscribers see on MYGN
- Value Score: is the price right for this business, the score the Value book is selected on.
- Trader Score: is it set up to move, refreshed every 15 minutes in the session.
- The full eight-axis breakdown, every input and its percentile.
- SEC filings, insider buying, earnings history and peers side by side.
- Whether it is in this week's published books, with the receipts.
Diagnostics & Research peers
| Stock | Company | Dad Score | Band |
|---|---|---|---|
| TMO | Thermo Fisher Scientific Inc. | 77.0 | good |
| DHR | Danaher Corporation | 79.6 | good |
| NTRA | Natera, Inc. | 86.1 | strong |
| A | Agilent Technologies, Inc. | 79.9 | good |
| IQV | IQVIA Holdings Inc. | 82.3 | good |
| WAT | Waters Corporation | 78.8 | good |
| ILMN | Illumina, Inc. | 35.1 | weak |
| IDXX | IDEXX Laboratories, Inc. | 90.1 | strong |
Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.